Developing a new treatment using live bacteria for ulcerative colitis
Official title: A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis
Funded at Rise Therapeutics, LLC · NIH-10894064 · Data updated 2026-11-12
This study is testing a new treatment that uses good bacteria from your body to help reduce gut inflammation for people with ulcerative colitis and Crohn's disease, aiming to improve your gut health with fewer side effects than current options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rise Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Rockville, UNITED STATES) |
| Project start | July 5, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $914,660 |
| NIH project number | 5R44DK133061-03 |
| Project ID | NIH-10894064 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with ulcerative colitis or Crohn's disease.
✕Less likely to help
Patients with other gastrointestinal disorders or those who are not diagnosed with inflammatory bowel disease may not benefit from this research.
What this research studies
This research aims to create a novel Live Biotherapeutic Product (LBP) that utilizes the body's natural microbiome to reduce inflammation in the gut, specifically targeting ulcerative colitis and Crohn's disease. The approach focuses on restoring the intestinal barrier and regulating immune responses to improve gut health. By leveraging beneficial bacteria, the treatment seeks to provide a safer alternative to current therapies, which often have significant side effects. Patients participating in this research may receive a new form of therapy that could help manage their condition more effectively.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment option for patients suffering from ulcerative colitis, potentially improving their quality of life.
How similar studies have gone: While the use of live biotherapeutics is an emerging field, previous studies have shown promise in utilizing microbiome-based therapies for inflammatory conditions, indicating potential success for this approach.
Where this research is happening
-
Rise Therapeutics, LLC
Rockville, United States Active
Researchers
- Principal investigator: Fanger, Gary — Rise Therapeutics, LLC
- Study coordinator: Fanger, Gary
Related research
Other NIH-funded projects on the same topics.
-
Outpatient pathway for severe ulcerative colitis in the right care setting
This study tests a safe, outpatient approach using an oral therapy and remote monitoring for people with acute severe ulcerative colitis to avoid hospitalization.
-
Fh15-based therapy to calm inflammation in sepsis and ulcerative colitis
A research project tests a molecule from a parasitic organism (Fh15) to reduce harmful inflammation in adults with sepsis or ulcerative colitis.
-
IMYX-3 treatment for ulcerative colitis
A new therapy approach called IMYX-3 aims to help adults with moderate to severe ulcerative colitis who have not responded well to current treatments.
-
Autoantibodies and ulcerative colitis: how avb6 antibodies may drive disease
This NIH grant aims to understand how antibodies against a gut cell protein (αvβ6) may actively contribute to ulcerative colitis and what that means for future treatments.
-
Selenium supplementation to help moderate-severe ulcerative colitis flare-ups
This grant tests whether giving selenium can help people with moderate to severe ulcerative colitis reduce flares and improve symptoms.
-
Development of TP-317 for Ulcerative Colitis
A new therapy approach for ulcerative colitis aims to repair the intestinal lining and restore immune balance in people with UC, addressing a need for patients who don’t fully respond to current treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.